(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 2.39%230.4B | 0.06%150.42B | -0.22%74.78B | 8.54%293.4B | 10.19%225.01B | 13.50%150.33B | 15.71%74.94B | 20.09%270.33B | 20.84%204.19B | 20.57%132.46B |
Operating income | 2.39%230.4B | 0.06%150.42B | -0.22%74.78B | 8.54%293.4B | 10.19%225.01B | 13.50%150.33B | 15.71%74.94B | 20.09%270.33B | 20.84%204.19B | 20.57%132.46B |
Operating expenses | 2.88%-185.4B | 5.22%-121.61B | 1.50%-62.36B | -8.45%-247.02B | -10.77%-190.9B | -16.90%-128.31B | -18.21%-63.31B | -19.67%-227.78B | -19.68%-172.34B | -16.82%-109.76B |
Gross profit | 31.94%45B | 30.80%28.81B | 6.69%12.42B | 9.01%46.38B | 7.08%34.11B | -2.96%22.02B | 3.75%11.64B | 22.43%42.54B | 27.52%31.85B | 42.69%22.7B |
Selling expenses | 3.85%-522.65M | -0.48%-343.94M | -10.93%-179.29M | -23.63%-766.39M | -10.61%-543.6M | -12.13%-342.31M | -10.47%-161.63M | -50.36%-619.89M | -49.36%-491.47M | -38.96%-305.28M |
Administrative expenses | 4.81%-5.15B | 3.33%-3.42B | 0.06%-1.79B | -20.08%-7.52B | -22.60%-5.41B | -22.59%-3.54B | -23.85%-1.79B | -18.02%-6.26B | -16.81%-4.41B | -16.25%-2.89B |
Research and development expenses | -1.99%-1.15B | 3.41%-708.16M | 0.43%-326.1M | -27.23%-1.57B | -41.37%-1.13B | -65.50%-733.16M | -85.24%-327.51M | -59.80%-1.23B | -59.74%-799.38M | -39.71%-442.99M |
Profit from asset sales | -68.47%5.83M | -205.03%-10.41M | -278.36%-6.59M | 815.07%37.31M | -34.88%18.49M | -67.03%9.91M | -107.13%-1.74M | 33.24%-5.22M | 352.93%28.39M | 3,443.56%30.05M |
Revaluation surplus | 5,640.17%1.01B | -429.01%-579.35M | -26.18%61.74M | 92.71%-18.62M | 103.60%17.56M | 1,602.84%176.09M | 273.34%83.63M | -10.19%-255.49M | -92.79%-488.34M | 92.18%-11.72M |
-Changes in the fair value of other assets | 5,640.17%1.01B | -429.01%-579.35M | -26.18%61.74M | 92.71%-18.62M | 103.60%17.56M | 1,602.84%176.09M | 273.34%83.63M | -10.19%-255.49M | -92.79%-488.34M | 92.18%-11.72M |
Impairment and provision | -315.23%-124.17M | -94.47%3.98M | 1,658.30%17.58M | -27.18%-519.05M | 259.92%57.69M | 163.70%71.93M | -92.97%999.73K | -1,947.90%-408.12M | -107.03%-36.08M | -122.64%-112.92M |
-Other impairment is provision | -315.23%-124.17M | -94.47%3.98M | 1,658.30%17.58M | -27.18%-519.05M | 259.92%57.69M | 163.70%71.93M | -92.97%999.73K | -1,947.90%-408.12M | -107.03%-36.08M | -122.64%-112.92M |
Special items of operating profit | 10.20%3.23B | 29.47%2.3B | 33.04%916.03M | 20.06%4.03B | -15.49%2.93B | -24.15%1.78B | -17.85%688.55M | 64.45%3.36B | 126.37%3.47B | 215.12%2.35B |
Operating profit | 43.35%38.1B | 35.59%23.34B | 9.68%9.88B | 7.17%35.21B | 2.05%26.58B | -10.50%17.21B | -3.32%9.01B | 23.58%32.85B | 31.87%26.04B | 55.31%19.23B |
Financing cost | 0.14%-2.26B | 7.79%-1.36B | 0.60%-803.08M | -71.57%-3.27B | -153.08%-2.26B | -184.11%-1.47B | -138.70%-807.91M | -27.30%-1.9B | 19.37%-892.3M | 31.07%-517.86M |
Special items of earning before tax | -36.97%-522.67M | -100.37%-396.38M | -169.73%-252.55M | 31.88%-649.06M | -38.36%-381.6M | -34.71%-197.82M | -31.00%-93.63M | -225.51%-952.76M | -36.09%-275.81M | 10.39%-146.85M |
Earning before tax | 47.56%35.33B | 38.87%21.59B | 8.86%8.83B | 4.32%31.29B | -3.77%23.94B | -16.29%15.55B | -8.99%8.11B | 20.97%29.99B | 34.90%24.88B | 61.90%18.57B |
Tax | -46.00%-5.65B | -14.75%-3.11B | 4.33%-1.18B | 9.14%-4.75B | 7.66%-3.87B | 13.61%-2.71B | 17.57%-1.23B | -0.61%-5.23B | -7.19%-4.19B | -22.68%-3.14B |
After-tax profit from continuing operations | 47.86%29.68B | 43.97%18.48B | 11.23%7.65B | 7.16%26.54B | -2.98%20.07B | -16.83%12.83B | -7.26%6.88B | 26.37%24.77B | 42.35%20.69B | 73.17%15.43B |
Earning after tax | 47.86%29.68B | 43.97%18.48B | 11.23%7.65B | 7.16%26.54B | -2.98%20.07B | -16.83%12.83B | -7.26%6.88B | 26.37%24.77B | 42.35%20.69B | 73.17%15.43B |
Minority profit | 36.18%5.32B | 34.00%3.39B | -3.28%1.39B | 14.71%5.42B | -2.83%3.91B | -9.62%2.53B | 11.12%1.44B | 20.33%4.73B | 24.46%4.02B | 23.83%2.8B |
Profit attributable to shareholders | 50.68%24.36B | 46.42%15.08B | 15.05%6.26B | 5.38%21.12B | -3.01%16.16B | -18.43%10.3B | -11.14%5.44B | 27.88%20.04B | 47.47%16.67B | 89.95%12.63B |
Basic earnings per share | 50.08%0.923 | 46.80%0.574 | 14.98%0.238 | 5.26%0.8 | -3.15%0.615 | -18.54%0.391 | -11.16%0.207 | 26.67%0.76 | 44.32%0.635 | 83.21%0.48 |
Diluted earnings per share | 49.11%0.917 | 46.55%0.573 | 14.98%0.238 | 5.26%0.8 | -3.15%0.615 | -18.54%0.391 | -11.16%0.207 | 26.67%0.76 | 44.32%0.635 | 83.21%0.48 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data